Loading cancer entity…
Loading cancer entity…
Clinical trials
115 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05786924 | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | recruiting | Phase 1 / Phase 2 | 554 | Institut de Recherches Internationales ServierOTHER | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06690827 | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03113643 | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | recruiting | Phase 1 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04318678 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | recruiting | Phase 1 | 108 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05950802 | Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta(ODIN) | recruiting | Phase 1 | 40 | University Health Network, TorontoOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials